One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
Price : 100$- Special Price : 50$
First phase 3 trial of GLP-1 receptor agonist for neurodegeneration
The RDI–Lancet Commission on Rare Diseases: improving visibility to address health-care disparities for 400 million people
Identifying key randomised clinical trials that could transform clinical care and public health
Spinal muscular atrophy in the UK: the human toll of slow decisions
Gender removal by fiat: impacts of new Trump administration edicts
Health-care system adaptability during wildfire disasters: crucial insights from LA County
Reflections on The Lancet's Commission on dementia prevention, intervention, and care
Reflections on The Lancet's Commission on dementia prevention, intervention, and care
Reflections on The Lancet's Commission on dementia prevention, intervention, and care
Reflections on The Lancet's Commission on dementia prevention, intervention, and care
Reflections on The Lancet's Commission on dementia prevention, intervention, and care – Authors' reply
Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial
Endoscopic, ultrasound-guided, radiofrequency ablation of aldosterone-producing adenomas (FABULAS): a UK, multicentre, prospective, proof-of-concept trial
Gene therapy in children with AIPL1-associated severe retinal dystrophy: an open-label, first-in-human interventional study
